VERISANTE TECHNOLOGY Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VERISANTE TECHNOLOGY

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: croman	10/6/2011 10:16:57 AM
	of 254

VERISANTE applies to HC to sell product in canada VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 6, 2011) - Verisante Technology, Inc. ( TSX VENTURE:VRS)(OTCQX:VRSEF)(PINK SHEETS:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer imaging technology, announced today that it has filed an application with Health Canada for a Class II Medical Device License to market and sell Verisante Aura(TM), a non-invasive medical device for the detection of skin cancer, in Canada. The Company has completed all applicable safety testing required under Health Canada guidelines. Additional safety testing is also being done to confirm compliance with European guidelines. This additional testing is required to complete the Technical File for submission to a notified body to receive CE Mark approval for Europe. Verisante anticipates submitting our Technical File in October. "We have come a long way and have met many milestones since licensing this technology from the BC Cancer Agency only 15 months ago," said President and CEO Thomas Braun. "As we move into the final quarter of 2011, we remain confident we will be able to meet our regulatory milestones of Canadian, European, and Australian approval by the end of the year."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext